CereMark Pharma™ LLC, a West Virginia limited liability corporation, was formed in 2013 by a group of physicians, scientists and attorneys with recognized expertise and distinguished careers in research and support of individuals who have experienced traumatic brain injury, or Alzheimer’s disease or both. The mission of CereMark Pharma™ is to license and develop new molecules as investigational new drugs to enable better diagnosis and treatment of tau- and amyloid-linked pathologies of the brain resulting from either disease or traumatic brain injury. CereMark Pharma™ LLC has licensed all rights to F-18 Flornaptitril (fka, F-18 FDDNP) from UCLA, where researchers created and first reported research findings on F-18 Flornaptitril’s ability to provide tau- and amyloid-related PET images of living subjects with Alzheimer’s disease and suspected CTE. F-18 Flornaptitril is an investigational new drug limited to research pursuant to FDA guidelines and restrictions.